Litigation & Arbitration,
Health Care & Hospital Law,
Antitrust & Trade Reg.
Jun. 29, 2023
HIV drug antitrust case against Gilead, Teva goes to jury
The plaintiffs accused Gilead of forging a deal with Teva, which had challenged many of Gilead’s vulnerable patents, to delay Teva’s marketing of its generic medicine and afford Gilead time to move its customers away from its current version of drugs to a newer medicine that did not have generic versions.
Attorneys in a sprawling antitrust case accusing pharmaceutical giant Gilead Sciences Inc. of scheming with Teva Pharmaceuticals USA Inc. to maintain a monopoly on HIV medication delivered closing arguments on Wednesday, kicking off jury deliberation.
“The evidence simply does not support a claim that Gilead and Teva made some agreement whereby Teva agreed to delay its entry into the marketplace. In fact, they came earlier,” said Bart H. W...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In